Clinical Trial Update: Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC. [Phase 2]

View source ↗

Summary

Phase 2 trial update examining neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (LARC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms
• Rectal Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Beijing Friendship Hospital | Conditions: Colorectal Neoplasms | Phase 2 | Status: UNKNOWN